INCYTE CORP (INCY) vs VERTEX PHARMACEUTICALS INC / MA (VRTX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | INCY | VRTX |
|---|---|---|
| Sector | Industrials | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $5.14B | $12B |
| Revenue growth (YoY) | ▲ 21.2% | ▲ 8.9% |
| Net income | $1.29B | $3.95B |
| Gross margin | 92.8% | 86.2% |
| Diluted EPS | $6.41 | $15.32 |
| Insider net (6 mo) | +131.3K sh • 15 sells • 0 buys | +809 sh • 14 sells • 0 buys |
| Institutional owners | 44 | 47 |
| Institutional value held | $12.27B | $86.39B |
| Next earnings (est.) | Oct 27, 2026 | Nov 2, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About INCYTE CORP (INCY)
Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, with additional operations in Morges, Switzerland; Tokyo, Japan; and Montreal, Canada, focused on the discovery, development, and commercialization of proprietary therapeutics… Read more →
About VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing transformative medicines for people with serious diseases, concentrating on specialty markets. Read more →
Source: SEC EDGAR.